secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001213900-25-062099
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius regains compliance with Nasdaq minimum bid price requirement
-------------------------------------------------------------------

- Nasdaq confirmed compliance with Listing Rule 5550(a)(2) after 10 consecutive trading days with bid price at $1.00 or greater.
- Compliance period from June 20, 2025 to July 3, 2025; previously scheduled hearing panel cancelled.
- CTXR common stock will continue to be listed and traded on Nasdaq Capital Market.
- Chairman and CEO Leonard Mazur stated the company remains focused on critical care products and shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025062099/0001213900-25-062099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025062099/ea0248335-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer